Literature DB >> 33691657

A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.

Wenqun Xing1, Haibo Sun2, Chi Yan3,4, Chengzhi Zhao3,4, Dongqing Wang3,4, Mingming Li5, Jie Ma6,7.   

Abstract

BACKGROUND: Lung cancer remains the leading cause of cancer deaths across the world. Early detection of lung cancer by low-dose computed tomography (LDCT) can reduce the mortality rate. However, making a definitive preoperative diagnosis of malignant pulmonary nodules (PNs) found by LDCT is a clinical challenge. This study aimed to develop a prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant pulmonary nodules from benign PNs.
METHODS: We assessed three DNA methylation biomarkers (PTGER4, RASSF1A, and SHOX2) and clinically-relevant variables in a training cohort of 110 individuals with PNs. Four machine-learning-based prediction models were established and compared, including the K-nearest neighbors (KNN), random forest (RF), support vector machine (SVM), and logistic regression (LR) algorithms. Variables of the best-performing algorithm (LR) were selected through stepwise use of Akaike's information criterion (AIC). The constructed prediction model was compared with the methylation biomarkers and the Mayo Clinic model using the non-parametric approach of DeLong et al. with the area under a receiver operator characteristic curve (AUC) analysis.
RESULTS: A prediction model was finally constructed based on three DNA methylation biomarkers and one radiological characteristic for identifying malignant from benign PNs. The developed prediction model achieved an AUC value of 0.951 in malignant PNs diagnosis, significantly higher than the three DNA methylation biomarkers (0.912, 95% CI:0.843-0.958, p = 0.013) or Mayo Clinic model (0.823, 95% CI:0.739-0.890, p = 0.001). Validation of the prediction model in the testing cohort of 100 subjects with PNs confirmed the diagnostic value.
CONCLUSION: We have shown that integrating DNA methylation biomarkers and radiological characteristics could more accurately identify lung cancer in subjects with CT-found PNs. The prediction model developed in our study may provide clinical utility in combination with LDCT to improve the over-all diagnosis of lung cancer.

Entities:  

Keywords:  Biomarkers; CT; DNA methylation; Lung cancer; Pulmonary nodules

Mesh:

Substances:

Year:  2021        PMID: 33691657      PMCID: PMC7944594          DOI: 10.1186/s12885-021-08002-4

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  27 in total

1.  Solitary pulmonary nodule: detection and management.

Authors:  S Diederich; M Das
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

2.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

Authors:  William D Travis; Elisabeth Brambilla; Andrew G Nicholson; Yasushi Yatabe; John H M Austin; Mary Beth Beasley; Lucian R Chirieac; Sanja Dacic; Edwina Duhig; Douglas B Flieder; Kim Geisinger; Fred R Hirsch; Yuichi Ishikawa; Keith M Kerr; Masayuki Noguchi; Giuseppe Pelosi; Charles A Powell; Ming Sound Tsao; Ignacio Wistuba
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

3.  Sample size estimation in diagnostic test studies of biomedical informatics.

Authors:  Karimollah Hajian-Tilaki
Journal:  J Biomed Inform       Date:  2014-02-26       Impact factor: 6.317

4.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

5.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

6.  SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.

Authors:  Christoph Kneip; Bernd Schmidt; Anke Seegebarth; Sabine Weickmann; Michael Fleischhacker; Volker Liebenberg; John K Field; Dimo Dietrich
Journal:  J Thorac Oncol       Date:  2011-10       Impact factor: 15.609

7.  The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules.

Authors:  S J Swensen; M D Silverstein; D M Ilstrup; C D Schleck; E S Edell
Journal:  Arch Intern Med       Date:  1997-04-28

8.  Overdiagnosis in low-dose computed tomography screening for lung cancer.

Authors:  Edward F Patz; Paul Pinsky; Constantine Gatsonis; Jorean D Sicks; Barnett S Kramer; Martin C Tammemägi; Caroline Chiles; William C Black; Denise R Aberle
Journal:  JAMA Intern Med       Date:  2014-02-01       Impact factor: 21.873

9.  The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes.

Authors:  Leng Han; Yuan Yuan; Siyuan Zheng; Yang Yang; Jun Li; Mary E Edgerton; Lixia Diao; Yanxun Xu; Roeland G W Verhaak; Han Liang
Journal:  Nat Commun       Date:  2014-07-07       Impact factor: 14.919

10.  Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.

Authors:  Gunter Weiss; Anne Schlegel; Denise Kottwitz; Thomas König; Reimo Tetzner
Journal:  J Thorac Oncol       Date:  2016-08-18       Impact factor: 15.609

View more
  1 in total

1.  Overview of recent advances in molecular analysis for diagnosing early stage lung cancer nodules.

Authors:  Milo Frattini; Patrizia Froesch; Samantha Epistolio
Journal:  Transl Lung Cancer Res       Date:  2021-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.